RT Journal Article
SR Electronic
T1 Response to Tocilizumab in Rheumatoid Arthritis Is Not Influenced by the Body Mass Index of the Patient
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 580
OP 584
DO 10.3899/jrheum.140673
VO 42
IS 4
A1 Yves-Marie Pers
A1 Marie Godfrin-Valnet
A1 Joseph Lambert
A1 Clémentine Fortunet
A1 Elodie Constant
A1 Thibault Mura
A1 Béatrice Pallot-Prades
A1 Christian Jorgensen
A1 Jean-Francis Maillefert
A1 Hubert Marotte
A1 Daniel Wendling
A1 Philippe Gaudin
YR 2015
UL http://www.jrheum.org/content/42/4/580.abstract
AB Objective. To assess the relationship between the body mass index (BMI) and the efficacy of tocilizumab (TCZ) in patients with rheumatoid arthritis (RA). Methods. We conducted a retrospective study in 222 patients with RA followed by 5 centers. The European League Against Rheumatism response was evaluated at 6 months. Univariate and multivariate logistic regressions were performed. Results. No significant association between the BMI and the response to TCZ at 6 months was found after adjustment for potential confounding factors (adjusted OR 0.45, 95% CI 0.16–1.24, p = 0.13 and OR 1.19, 95% CI 0.31–4.48, p = 0.78 for BMI 25–30 kg/m2 and BMI > 30 kg/m2, respectively, compared to BMI < 25 kg/m2). Conclusion. Response to TCZ in patients with RA is not influenced by the baseline BMI, in contrast to anti-tumor necrosis factor drugs.